ethyl 3,3-bis[3-(trifluoromethyl)phenyl]acrylate | 462093-57-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3,3-bis[3-(trifluoromethyl)phenyl]acrylate
• 英文别名: ethyl 3,3-bis-(3-trifluorophenyl)-acrylate；ethyl 3,3-bis-(3-trifluormethylophenyl)-acrylate；Ethyl 3,3-bis[3-(trifluoromethyl)phenyl]prop-2-enoate
• CAS: 462093-57-8
• 化学式: C₁₉H₁₄F₆O₂
• 分子量: 388.309
• InChiKey: AJCRFIGUONCGCZ-UHFFFAOYSA-N

物化性质

• 沸点：
  393.4±37.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ethyl 3,3-bis[3-(trifluoromethyl)phenyl]acrylate 在 二异丁基氢化铝 、 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 丙酮 、 甲苯 为溶剂， 反应 25.0h， 生成 3-{3,3-bis[3-(trifluoromethyl)phenyl]prop-2-enyl}-9-propionyl-3,9-diazabicyclo[3.3.1]nonane
  参考文献：
  名称：

  N-3(9)-Arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as μ-Opioid receptor agonists. Effects on μ-Affinity of arylalkenyl chain modifications

  摘要：

  Two series of N-3-arylpropenyl-N-9-propionyl-3,9-diazabicyclo[3.3.1]nonanes (1b-j) and of the reverted N-3-propionyl-N-9-arylpropenyl isomers (2b-j) as analogues of the previously reported analgesic N-3(9)-cinnamyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes (DBN) (1a, 2a) were synthesised and their affinity and selectivity towards opioid mu-, delta- and K-receptors were evaluated. Several compounds (1e,i.j 2d,e,f,g,j) exhibited a p-affinity in the low nanomolar range with moderate or negligible affinity towards delta- and kappa-receptors. The representative term N-9-(3,3-diphonylprop-2-enyl)-N-3-propionyl-DBN (2d) displayed in vivo (mouse) a potent analgesic effect (ED50 3.88 mg/kg ip) which favourably compared with that of morphine (ED50 5 mg/kg ip). In addition, 2d produced in mice tolerance after a period twice as long with morphine. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00436-9
• 作为产物：
  描述：

  磷酰基乙酸三乙酯 、 3,3'-双(三氟甲基)苯甲酮 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.58h， 以69%的产率得到ethyl 3,3-bis[3-(trifluoromethyl)phenyl]acrylate
  参考文献：
  名称：

  Novel compounds, their preparation and use

  摘要：

  通用公式（I）的新化合物，这些化合物作为药物组成物的用途，包含这些化合物的药物组成物以及使用这些化合物和组成物的治疗方法。这些化合物可能在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，特别是PPARδ亚型。

  公开号：

  US20050070583A1

文献信息

• Novel compounds, their preparation and use
  申请人：Jeppesen Lone

  公开号：US20050070583A1

  公开（公告）日：2005-03-31

  Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ suptype.

  通用公式（I）的新化合物，这些化合物作为药物组成物的用途，包含这些化合物的药物组成物以及使用这些化合物和组成物的治疗方法。这些化合物可能在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，特别是PPARδ亚型。
• [EN] NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS<br/>[FR] NOUVEAUX COMPOSES, LEUR PREPARATION ET LEUR UTILISATION
  申请人：NOVO NORDISK AS

  公开号：WO2004037776A3

  公开（公告）日：2004-06-10
• NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS
  申请人：High Point Pharmaceuticals, LLC

  公开号：EP1558572B1

  公开（公告）日：2010-06-30
• US7129268B2
  申请人：——

  公开号：US7129268B2

  公开（公告）日：2006-10-31
• N-3(9)-Arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as μ-Opioid receptor agonists. Effects on μ-Affinity of arylalkenyl chain modifications
  作者：G Pinna

  DOI：10.1016/s0968-0896(01)00436-9

  日期：2002.6

  Two series of N-3-arylpropenyl-N-9-propionyl-3,9-diazabicyclo[3.3.1]nonanes (1b-j) and of the reverted N-3-propionyl-N-9-arylpropenyl isomers (2b-j) as analogues of the previously reported analgesic N-3(9)-cinnamyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes (DBN) (1a, 2a) were synthesised and their affinity and selectivity towards opioid mu-, delta- and K-receptors were evaluated. Several compounds (1e,i.j 2d,e,f,g,j) exhibited a p-affinity in the low nanomolar range with moderate or negligible affinity towards delta- and kappa-receptors. The representative term N-9-(3,3-diphonylprop-2-enyl)-N-3-propionyl-DBN (2d) displayed in vivo (mouse) a potent analgesic effect (ED50 3.88 mg/kg ip) which favourably compared with that of morphine (ED50 5 mg/kg ip). In addition, 2d produced in mice tolerance after a period twice as long with morphine. (C) 2002 Elsevier Science Ltd. All rights reserved.